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Complex rearrangements involving the MLL gene on chromosome 11q23 and MLLT10 on 10p have been reported in 15% of pediatric patients with MLL rearranged acute myelogeneous leukemia (AML). Owing to the opposite direction of MLL and MLLT10 rearrangements (inversion and subsequent translocation or insertion) with three or more breaks are required to result in a fusion gene. 1, 2 There are several additional reported recombination partners of the MLL gene, in which a simple reciprocal translocation is insufficient due to incompatible orientation. 3 However, even more complex rearrangements consisting of additional involved chromosomes have been described in t(10;11). 4 Chromosomal translocations t(10;11) (p12;q14-23) always lead to fusion of the 5 0 end of MLL and 3 0 end of MLLT10. The MLLT10 fusion partner codes for two adjacent alpha helical domains and a leucine zipper motif embedded within a region of 82 amino acids, proposed to be indispensable for induction of leukemia. 5, 6 The gold standard to detect suspected translocations in AML patients are fluorescence in situ hybridization (FISH) studies and subsequent reverse transcriptase-polymerase chain reaction (RT-PCR). However, next generation sequencing has emerged as a powerful tool to understand complex genetic traits. Here, we applied lowcoverage whole-genome sequencing on six pediatric patients with t(10;11) AML (FAB-M4/M5), in which MLL rearrangement and the MLL/MLLT10 fusion gene had been detected by conventional FISH and RT-PCR (Table S1 ). A specimen of the initial and remission sample was obtained in six children; in three of them a relapse sample was available and additionally analyzed after informed consent. By analyzing paired-end reads, we were able to describe these alterations in depth, revealing the precise pattern of molecular rearrangement and finding other involved chromosomes. For paired-end sequencing, DNA was isolated from peripheral blood lymphocytes, and fragment libraries with a median insert size of 450 bp were prepared. Samples of patients 1-3 were sequenced on a GAIIx platform; samples of patients 4-6 on a HiSeq 2000 (Illumina Inc., San Diego, CA, USA). A bioinformatical pipeline for read alignment, removal of duplicate reads and variant detection was applied to find structural alterations based on mapping coordinates, insert size and orientation of reads. By sequencing the remission sample we excluded inherited sequence variants. Copy number variations were detected by coverage normalization, and computation of copy number ratios between diseased and remission sample. Conventional PCR and capillary sequencing validated selected translocations detected by paired-end read analysis. For further methodical details we refer to our supplemental file.
Our pipeline was able to reveal the defining MLL/MLLT10 translocation with its precise genomic coordinates in each leukemic sample (except relapse in patient 4). Consistent with past publications we observed heterogeneity in breakpoints within the breakpoint cluster regions of MLL and MLLT10, Translocations  24  21  36  412  6  1  11  17  5  Deletions  3827  3108  1193  49  21  25  27  14  1  Inversions  15  13  14  16  0  0  11  12  3 Abbreviations: CNV, copy number variation; I, initial; R, relapse. In all patients, paired-end sequencing revealed the pattern of molecular rearrangement. ( þ ) indicates gains, ( À ) losses. Lower rows: number of detected structural variants. Patients 1-3 were sequenced on the GAIIx with a significant lower coverage, thus variants with at least two supporting reads have been counted; in patients 4-6 (HiSeq2000) variants had at least three supporting reads. The illustration consists of a normal reference genome in the upper region with found paired-end reads (for example, m1 and m1a) aligned to the genome. As each read (for example, m1) is supposed to be orientated to its mate (for example, m1a), the type of rearrangement can be deduced; for example, upper panel: m4a and m4 orientated towards each other suggest a deletion, m1 and m1a on different chromosomes suggest a translocation; lower panel: m2 and m2a are located on the same strand and are orientated in the same direction, indicating an inversion. (d) Upper panel: schematic overview of the complex translocations between chromosome 10, 11 and 22, harboring the MLL/MLLT10 fusion gene. Furthermore, the fusion gene RNF214/MLL is depicted. The fusion sequence MLL/MLLT10 and t(22;11) was further validated by capillary sequencing, revealing the breakpoint at one-bp level. Lower panel: schematic overview of the translocation harboring the MLL/MLLT10 fusion gene and MLLT10/RNF169 fusion gene. The latter fusion sequence was further validated by capillary sequencing, revealing the breakpoint at 1-bp level. (e) CIRCOS plot of the initial sample: genomic landscape of interchromosomal translocations were scattered across the whole genome and allocated along the outer ring (chromosome ideograms). The inner ring represents copy number status in terms of gains and losses. However, only variants supported by 42 reads (in patient 1-3) and 43 reads (in patient 4-6) were transferred into this plot (f ) CNV plot: deep blue-colored bars indicate the copy number determined by sequencing data in relation to the reference genome. In case of gains and losses bars are elevated or lowered.
respectively. Furthermore, we detected numerous structural variants in leukemic samples not found in the remission material (Table 1) . Briefly, we see classical t(10;11) rearrangements in patients 3 and 5, which were also found by cytogenetics and FISH. In patient 3 ( Figure S4 ), reads were found, suggestive of a missing region on chromosome 11 containing part of the MLL gene. Further reads suggested that this MLL gene fragment was subsequently inserted into the MLLT10 gene. In patient 5 ( Figure S5 ), reads indicated an inversion of a region of chromosome 11 that encodes partially for the MLL gene. Subsequently the inverted fragment and the q-terminal part was translocated into the MLLT10 gene. Validation PCR and capillary sequencing verified the MLL/MLLT10 breakpoint in both patients. In patient 1 and 4, in contrast to FISH and cytogenetics, paired-end analysis revealed the involvement of additional chromosomal material inserted at the t(10;11) breakpoint. In patient 1 ( Figure  S1 ), we saw an additional breakpoint on 16q23.3. In patient 4 ( Figure 1, upper panel) , reads indicated the involvement of three chromosomes (10, 11 and 22). We found read pairs on 11q23.3 (m4, m4a) orientated towards each other but encompassing a 1-Mb-spanning region, suggestive of a 'deletion'. Furthermore, at both ends of this region we found reads, which had their origin in the intronic region 5-6 of the MLLT10 gene (p12.31), leading to the MLL/MLLT10 fusion gene (m1, m1a), and at 22q12.3 (m3, m3a), respectively. In conclusion, a 1-Mb-spanning region on 11q23.3 was inserted on the derivative chromosome 10 between the MLLT10 region (p12.31) and the inverted 22q12.3. Reads m2 and m2a suggest that the telomeric part of the MLLT10 gene had been fused to 22q12.3 reciprocally.
In patient 6 ( Figure 1 , lower panel), we detected a new pattern of rearrangement. We detected reads, which were on the same strand and orientated in the same direction, instead of pointing towards each other. Therefore, m3 and m3a indicate an inversion between 11q13.4 and 11q24.2 as the first step of rearrangement. However, further paired-end reads suggest that only one part of the inverted region on chromosome 11 was inserted into chromosome 10. M2 and m2a suggested a 'deleted region' on the now inverted region between q13.4 and q23.3. M1 and m4a on chromosome 11 and the corresponding mates m1a and m4 in the MLLT10 gene indicated that this particular missing region (q13.4:q23.3) on the previously inverted part of 11q was inserted into MLLT10 (intronic region 9-10). Thus, on the derivative chromosome 11 the region of q23.4 to q24.2 remains in the inverted form. On chromosome 10, MLL exons 1-8 were fused in-frame to MLLT10 exons 9-24.
Interestingly, we observed in two patients additional rearrangements between a ring finger protein gene and MLL, beside the already described MLL-MLLT10 fusion. In patient 4, the rearrangement leads to an in-frame gene fusion RNF214/MLL (5 0 -exon1-5RNF214-exon9-36MLL-3 0 ). In silico analysis predicts a 315 kDa protein (2883aa). In patient 6, we observe an in-frame gene fusion MLLT10/RNF169 (5 0 -exon1-8MLLT10-exon3-6RNF169-3 0 ; in silico prediction: 87 kDa protein, 781 aa). See Figure S6 for orientation and location of the corresponding genes.
Copy number profiling revealed copy number variation in patient 2 (gains on chromosomes 1,14 and 21, losses on chromosome 2). In patient 6, cytogenetics detected an additional marker chromosome and a loss of chromosome 17 (46,XY,der(10)t(10;11) (p12;q23)inv(11)(q13q23), der(11)t(10;11)(p12;q13),-17, þ mar(9)/45, idem,-Y(2)/46,XY(3)). Copy number variation data identified a large gain on chromosome 8, but no loss of chromosome 17. Therefore, it might be suggested that the marker consists of chromosome 17 and long arm material of chromosome 8 (Figure 1a and d) .
For a more detailed description of sequencing data and results, we refer to our supplementary data. In summary, in each sample we were able to reveal the complex mechanism leading to a translocation t(10;11) with at least three subsequent breakpoints and rearrangements. Owing to manual inspection of sequencing reads, we could exactly deduce the molecular anatomy of the rearrangement. In patients 3, 4 and 6, we found an inversion followed by an insertion, in patient 1, 2 and 5 an inversion followed by a translocation. Van Limbergen 7 classified these reported molecular rearrangements as type I (patients 3, 4 and 6) and type II (patients 1, 2 and 5). In most patients we determined the breakpoints down to the nucleotide level by validating the breakpoint by PCR. We identified additional chromosomal fusions that were not being detected by routine cytogenetics; in patient 6 we found a new subtype of rearrangement, which has not been described before. Though FISH probes and cytogenetic banding techniques clearly identify the t(10;11) MLLT10/MLL translocation, paired-end sequencing allowed to identify additional structural variants. It is certainly of great interest to know how many of the other previously reported t(10;11) harbor this type of rearrangement. In two patients we observed the reciprocal fusion of ring finger protein genes to the 3 0 MLL gene. RNF214 consists of a conserved cysteine-rich domain that is able to bind zinc atoms. Proteins with this domain are mostly involved in the ubiquitination pathway of protein degradation. In recent publications, RNF169 was identified as a paralog to RNF168. 8, 9 RNF8/RNF168 signaling is involved in the repair pathway of double stranded breaks; RNF169 is supposed to regulate this signaling pathway in magnitude. 9 However, the precise function of RNF214 and RNF168, and their possible effects as reciprocal MLL fusion protein remains to be determined. Finally, copy number profiling was able to comprehensively disclose chromosomal gains and losses; for example, in patient 6 the origin of a marker chromosome seen cytogenetically was clarified.
In conclusion, we were able to decipher the complex MLL/ MLLT10 gene configuration found in our patients. Numerous reports have dealt with MLL/MLLT10 patients, also revealing complex karyotypes after different serial diagnostic methods. Our method offers a time-efficient one-way method to discover the underlying alteration at a high resolution on base pair level. This indicates that at least in patients with unclear FISH or cytogenetic findings, this method should be strongly considered, as sequencing costs have also been decreasing gradually. Analytic pipelines for clinical diagnostic approaches will also need to be optimized for detection of different types of variants and modified to the clinical condition.
As highlighted in our study, the involvement of ring-type Zinc finger genes (examples also found in promyelocytic leukemia) is of particular interest as therapeutic strategies might evolve from future shared findings in other patients.
